Payment overview · 2025
General Payments
$1,405.30
26 reported records · 11 companies
Healthcare provider profile · identity verified
Grant Jester, M.D.
Allopathic & Osteopathic Physicians|Internal Medicine · GAINESVILLE, FL · NPI 1275952947
Verified facts
What the public records show
CMS Open Payments records show Grant Jester, M.D. received $1,405.30 in general payments during 2025 across 26 reported records.
Novartis Pharmaceuticals Corporation accounted for 71.2% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 13 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Erleada.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Xtandi as an associated drug or biological on 11345 records involving 5418 distinct recipient NPIs. Public Medicare Part D data also shows 15 claims for Xtandi by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 32382 records involving 10919 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Erleada by this doctor in 2024.
Janssen Biotech, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported XARELTO as an associated drug or biological on 24 records involving 23 distinct recipient NPIs. Public Medicare Part D data also shows 99 claims for Xarelto by this doctor in 2024.
Janssen Scientific Affairs, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ERLEADA as an associated drug or biological on 1106 records involving 808 distinct recipient NPIs. Public Medicare Part D data also shows 27 claims for Erleada by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROMACTA as an associated drug or biological on 47 records involving 47 distinct recipient NPIs. Public Medicare Part D data also shows 12 claims for Promacta by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $999.96 | 71.2% | 12 | 2025 |
| Janssen Biotech, Inc. | Unresolved — no canonical attribution shown | $145.57 | 10.4% | 3 | 2025 |
| Pharmacosmos Therapeutics Inc. | Unresolved — no canonical attribution shown | $42.00 | 3.0% | 2 | 2025 |
| Daiichi Sankyo Inc. | Unresolved — no canonical attribution shown | $41.42 | 3.0% | 2 | 2025 |
| Janssen Scientific Affairs, LLC | Unresolved — no canonical attribution shown | $29.10 | 2.1% | 1 | 2025 |
| PharmaEssentia USA Corporation | Unresolved — no canonical attribution shown | $28.16 | 2.0% | 1 | 2025 |
| Dendreon Pharmaceuticals LLC | Unresolved — no canonical attribution shown | $27.82 | 2.0% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $24.79 | 1.8% | 1 | 2025 |
| Caris MPI, Inc. | Unresolved — no canonical attribution shown | $23.65 | 1.7% | 1 | 2025 |
| Delcath Systems | Unresolved — no canonical attribution shown | $23.29 | 1.7% | 1 | 2025 |
| Karyopharm Therapeutics Inc. | Unresolved — no canonical attribution shown | $19.54 | 1.4% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Long term medical supply or device loan | $999.96 | 12 |
| Food and Beverage | $405.34 | 14 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| KISQALI Normalized: kisqali |
Drug | Novartis Pharmaceuticals Corporation | $999.96 | 12 | 2025 |
Source payment records
|
|||||
| RYBREVANT Normalized: rybrevant |
Drug | Janssen Biotech, Inc. | $145.57 | 3 | 2025 |
Source payment records
|
|||||
| CARVYKTI Normalized: carvykti |
Drug | Janssen Biotech, Inc. | $103.09 | 1 | 2025 |
Source payment records
|
|||||
| MONOFERRIC Normalized: monoferric |
Drug | Pharmacosmos Therapeutics Inc. | $42.00 | 2 | 2025 |
Source payment records
|
|||||
| Vanflyta Normalized: vanflyta |
Drug | Daiichi Sankyo Inc. | $41.42 | 2 | 2025 |
Source payment records
|
|||||
| BALVERSA Normalized: balversa |
Drug | Janssen Scientific Affairs, LLC | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| ERLEADA Normalized: erleada |
Drug | Janssen Scientific Affairs, LLC | $29.10 | 1 | 2025 |
Source payment records
|
|||||
| BESREMI Normalized: besremi |
Drug | PharmaEssentia USA Corporation | $28.16 | 1 | 2025 |
Source payment records
|
|||||
| PROVENGE Normalized: provenge |
Drug | Dendreon Pharmaceuticals LLC | $27.82 | 1 | 2025 |
Source payment records
|
|||||
| Vyloy Normalized: vyloy |
Drug | Astellas Pharma US Inc | $24.79 | 1 | 2025 |
Source payment records
|
|||||
| MI CANCER SEEK Normalized: mi cancer seek |
Device | Caris MPI, Inc. | $23.65 | 1 | 2025 |
Source payment records
|
|||||
| HEPZATO KIT Normalized: hepzato kit |
Drug | Delcath Systems | $23.29 | 1 | 2025 |
Source payment records
|
|||||
| XPOVIO Normalized: xpovio |
Drug | Karyopharm Therapeutics Inc. | $19.54 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ERLEADA erleada |
2025 | Erleada | 2024 | 27 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Xtandi open payments reported associated product |
CMS Open Payments — General Payments 11345 supporting records · 5418 recipient NPIs · example record 1238560686 |
Xtandi · 2024 Exact normalized brand match · 1 Part D row |
15 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 32382 supporting records · 10919 recipient NPIs · example record 1174257499 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Janssen Biotech, Inc. Exact reporting entity; no affiliate inference |
2025 | XARELTO open payments reported associated product |
CMS Open Payments — General Payments 24 supporting records · 23 recipient NPIs · example record 1174259978 |
Xarelto · 2024 Exact normalized brand match · 1 Part D row |
99 | 20 |
| Janssen Scientific Affairs, LLC Exact reporting entity; no affiliate inference |
2025 | ERLEADA open payments reported associated product |
CMS Open Payments — General Payments 1106 supporting records · 808 recipient NPIs · example record 1174147601 |
Erleada · 2024 Exact normalized brand match · 1 Part D row |
27 | suppressed by CMS |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | PROMACTA open payments reported associated product |
CMS Open Payments — General Payments 47 supporting records · 47 recipient NPIs · example record 1200028032 |
Promacta · 2024 Exact normalized brand match · 1 Part D row |
12 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 231 | 59 |
| Xarelto | Rivaroxaban | 99 | 20 |
| Prednisone | Prednisone | 89 | 43 |
| Anastrozole | Anastrozole | 73 | 24 |
| Ondansetron Hcl | Ondansetron Hcl | 71 | 56 |
| Oxycodone Hcl | Oxycodone Hcl | 66 | 30 |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 62 | 43 |
| Acyclovir | Acyclovir | 61 | 16 |
| Mirtazapine | Mirtazapine | 53 | 16 |
| Hydroxyurea | Hydroxyurea | 41 | suppressed |
| Abiraterone Acetate | Abiraterone Acetate | 40 | suppressed |
| Lidocaine-Prilocaine | Lidocaine/Prilocaine | 38 | 29 |
| Gabapentin | Gabapentin | 37 | 12 |
| Lorazepam | Lorazepam | 35 | 16 |
| Trazodone Hcl | Trazodone Hcl | 32 | suppressed |
| Erleada | Apalutamide | 27 | suppressed |
| Nubeqa | Darolutamide | 23 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 23 | suppressed |
| Dexamethasone | Dexamethasone | 22 | 17 |
| Tamsulosin Hcl | Tamsulosin Hcl | 21 | suppressed |
| Dicyclomine Hcl | Dicyclomine Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 20 | suppressed |
| Furosemide | Furosemide | 19 | 11 |
| Levothyroxine Sodium | Levothyroxine Sodium | 17 | suppressed |
| Tagrisso | Osimertinib Mesylate | 17 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 17 | suppressed |
| Azithromycin | Azithromycin | 15 | 14 |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 15 | suppressed |
| Potassium Chloride | Potassium Chloride | 15 | suppressed |
| Xtandi | Enzalutamide | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 13 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 13 | suppressed |
| Allopurinol | Allopurinol | 12 | suppressed |
| Lactulose | Lactulose | 12 | 11 |
| Lenalidomide | Lenalidomide | 12 | suppressed |
| Lumakras | Sotorasib | 12 | suppressed |
| Pomalyst | Pomalidomide | 12 | suppressed |
| Promacta | Eltrombopag Olamine | 12 | suppressed |
| Fentanyl | Fentanyl | 11 | suppressed |
| Folic Acid | Folic Acid | 11 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,405.30 · 26 records | Novartis Pharmaceuticals Corporation | BALVERSA, BESREMI, CARVYKTI, ERLEADA, HEPZATO KIT, KISQALI, MI CANCER SEEK, MONOFERRIC, PROVENGE, RYBREVANT, Vanflyta, Vyloy, XPOVIO | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Erleada play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with Astellas Pharma US Inc?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error